Background: Expanding contraceptive options could better meet users' diverse needs and preferences. Annovera is a contraceptive vaginal ring that provides a year of pregnancy prevention while remaining under user control and allowing for regular menstrual cycles. This method may also help to reduce burdens on some health care and supply chain systems. However, knowledge gaps exist regarding initial and ongoing acceptability of contraceptive vaginal rings in African settings.
Methods: We will undertake an open-label, non-randomized, two-arm, parallel clinical acceptability study with an embedded qualitative component, based in clinics providing contraceptive services in Kenya and Zimbabwe. Women aged 18-45 interested in newly initiating or switching contraception will choose from among all available contraceptive options, including Annovera. We aim to enroll 200 participants selecting Annovera and 200 participants selecting either contraceptive injectables or pills. We will compare method uptake, continuation, and satisfaction over one year. Participants will complete questionnaires administered by study staff during two in-person visits (a screening/enrollment visit, and an end of study visit after 52 weeks of method use or at discontinuation) and four phone appointments (at 4, 12, 24, and 36 weeks of use). We will evaluate used rings for discoloration and residual drug levels. The qualitative component involve in-depth interviews with women in the clinical study, their sexual partners, and their service providers, to further examine drivers of and barriers to interest in and use of contraceptive vaginal rings.
Discussion: This study will explore acceptability of contraceptive vaginal rings in 'real-world' contraceptive service settings in two African countries. Findings will be based on actual ring use and contextualized via comparison to two other commonly available methods. As vaginal rings are being considered for multiple reproductive health indications, this work can fill key knowledge gaps and empower decision-makers with information needed to inform future investments in reproductive health.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876155 | PMC |
http://dx.doi.org/10.12688/gatesopenres.16315.1 | DOI Listing |
Am J Obstet Gynecol
March 2025
Population Council, Center for Biomedical Research, New York, NY.
Background: No empirical data support the 54-58mm external diameter of intravaginal rings (rings) currently available and in development for contraception and other indications. Understanding how external diameter affects preference, adherence, and acceptability is critical for optimizing future product development.
Objectives: Our primary objectives were to determine which of three non-medicated rings of differing external diameters was preferred and yielded the highest adherence.
Int J Pharm
March 2025
School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK. Electronic address:
A dapivirine (DPV)-releasing vaginal ring (DapiRing®, containing 25 mg DPV) has been approved in various African countries for prevention of human immunodeficiency virus type 1 (HIV-1). Current research is focused on next-generation multipurpose prevention technology (MPT) vaginal rings that additionally provide contraception, and a combination dapivirine + levonorgestrel ring is in clinical development. However, hormonal contraceptives have numerous side effects and contraindications, and many women are interested in hormone-free contraceptive options.
View Article and Find Full Text PDFFront Cell Infect Microbiol
March 2025
Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran.
The vaginal microbiome of healthy women is dominated by spp. A variety of illnesses, such as vaginosis, sexually transmitted infections (STIs), failed implantation, premature birth (PTB), and preterm pre-labor membrane rupture, are brought on by an unbalanced microbiota. Pregnancy is associated with a decrease in the metabolic capacity of the vaginal resident microbiome, which is consistent with a change to a less complex -dominated microbiome.
View Article and Find Full Text PDFGates Open Res
March 2025
Médecins Sans Frontières, Harare, Zimbabwe.
Background: Expanding contraceptive options could better meet users' diverse needs and preferences. Annovera is a contraceptive vaginal ring that provides a year of pregnancy prevention while remaining under user control and allowing for regular menstrual cycles. This method may also help to reduce burdens on some health care and supply chain systems.
View Article and Find Full Text PDFInfect Drug Resist
February 2025
Department of Gynecology, Jinan Second Maternal and Child Health Hospital, Jinan, People's Republic of China.
Objective: This study aims to investigate the clinical characteristics of vaginal trichomoniasis infection among vaginitis patients and assess their resistance to metronidazole.
Methods: We conducted a retrospective study involving 687 vaginitis patients who visited our hospital from April 2022 to June 2024. Clinical data were collected through questionnaires that included information on age, occupation, season of infection, marital status, contraceptive methods, and frequency of vulvar hygiene.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!